Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 19/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503696 | 0.92 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6512027 | 0.91 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6508100 | 0.90 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6509045 | 0.87 | ADORA2A (1.00) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6503734 | 0.85 | ADORA2B (0.79) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6511119 | 0.84 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6504873 | 0.84 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6503777 | 0.82 | ADORA2B (0.73) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6502217 | 0.82 | ADORA2A (0.76) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6508242 | 0.81 | ADORA2B (1.00) | ADORA2BADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005033068-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | OY JUVANTIA PHARMA LTD (FI) | 2005-04-14 | — | — | WO | disclosed |
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ADORA1, ADORA2A, P2RY10 | ADORA2B 4/4885ADORA2A 2/4885ADORA3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.